For a business built on orthopaedics and wound care, Smith & Nephew PLC (LSE:SN) has given investors a fair bit of whiplash.
Its third-quarter update sent the shares down about 10% after organic revenue growth came in weaker than hoped and, crucially, slowed from the second quarter despite earlier guidance that it would accelerate.
UBS says the numbers were not disastrous in themselves, but sentiment had run ahead of reality and a cluster of headwinds now threatens to slow margin progress next year.
The broker still thinks the company can manage 4-5% revenue growth and eventually lift margins towards 21%.
Even so, it sees some risk to 2026 expectations and argues the shares now sit roughly where they should, trading close to their three to five-year average relative to the wider medical devices sector.
Attention turns to the Capital Markets Day in London on 8 December. Investors are hoping for a fresh mid-term guidance range, probably centred on mid-single digit organic revenue growth and a return to operating margins above 22%, the level seen before the pandemic.
UBS cautions that any bolder revenue ambition would likely be viewed with scepticism, so a measured approach could land better. For 2026, its own model assumes 4% organic growth and a modest 40 basis-point margin lift.
Forecast tweaks are minor. Revenue estimates for 2025 to 2029 are largely unchanged, while margins for 2025 rise on the back of management’s comments, pushing adjusted operating profit up by 3%.
Forecasts ease slightly for 2026 and 2027, although expected cost savings later in the decade lift outer-year numbers. A recently announced $500 million buyback, followed by $250 million a year thereafter, nudges adjusted earnings per share up by 5–10%.
UBS has inched its valuation up to £12.90 from £12.50, based on a discounted cash flow model. That implies about 15 times 2026 earnings, a discount of 15–20% to the sector and in line with historical norms.
With only a sliver of upside to its target price, the 'neutral' rating stays put.